RE:sirona is alive From Dividend stocks.com :
AbbVie Inc. (NYSE:ABBV) stock is down 3% in midday trading after the company posted a mixed earnings report. However, that’s a significant improvement from where AbbVie stock opened. In the pre-market, the stock dropped 6% after the released report.
This seems to be a case of ready, fire, aim. As investors have had a chance to look at the report, there’s not a lot of unexpected news. By now, the fact that AbbVie will lose patent protection on Humira is old news. In fact, that news — along with the broader macroeconomic drop — has been holding AbbVie stock down for most of the year.
Prior to the earnings report, ABBV stock was up 7% in the past month. That had pushed the stock past two key technical levels. Specifically, the stock had moved above both its 50- and 200-day ascending moving averages.
After the initial gap down, the stock holds above those levels, which may indicate that there’s more room for ABBV stock to run.